Loading
Loading
Research Overview
Short di- to tetrapeptide bioregulators developed by Prof. Vladimir Khavinson; hypothesised to penetrate cell nuclei and bind chromatin, restoring gene expression patterns in age-related tissue decline by acting as epigenetic regulators for organ-specific cell types.
Khavinson bioregulators are ultra-short peptides (di-, tri-, and tetrapeptides) derived from tissue extracts and synthesised for use in preclinical research. The principal mechanistic hypothesis studied in preclinical settings is that these short peptides can penetrate cell nuclei and interact with complementary DNA sequences at gene promoter regions, potentially influencing gene transcription for tissue-specific proteins. This gene-regulatory mechanism has been examined in cell culture and animal model studies for a range of short peptides targeting different tissue types.
Among the best-studied Khavinson peptides in preclinical settings are tissue-specific peptides including Epithalon (epitalon), a tetrapeptide studied for telomere biology and pineal gland function; Thymalin and Thymulin, studied for thymic and immune cell biology; Cortagen, studied for cardiac and vascular biology; and Vilon, studied for immune modulation. Multiple additional short peptides targeting specific tissues including liver, cartilage, ovary, prostate, lung, and vascular tissue have been characterised in preclinical studies.
Preclinical research on Khavinson bioregulators has been conducted primarily in Soviet and Russian research institutions over several decades. Studies have examined peptide effects on longevity markers, immune function, organ-specific gene expression, and age-related biological changes in animal models. These studies have employed a range of biochemical, histological, and functional endpoints to characterise biological activity.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, khavinson short peptide bioregulators has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Khavinson Short Peptide Bioregulators research is most relevant to protocols examining:
Organ-specific ageing and epigenetic gene expression research
Khavinson bioregulator framework investigations across tissue types
Longevity protocol research using cycled peptide bioregulators
Researchers interested in chromatin-binding peptide mechanisms
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Short di- to tetrapeptide bioregulators developed by Prof. Vladimir Khavinson; hypothesised to penetrate cell nuclei and bind chromatin, restoring gene expression patterns in age-related tissue decline by acting as epigenetic regulators for organ-specific cell types.
| Parameter | Value |
|---|---|
| Dose range | 10–20 mg/day (10–20 day cycles) |
| Schedule | Daily (cycled 2–3× per year) |
| Route | Subcutaneous |
| Half-life | ~Hours |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.